Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback